Media coverage about EnteroMedics (NASDAQ:RSLS) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. EnteroMedics earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave press coverage about the medical device company an impact score of 47.3626137106087 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the news stories that may have effected Accern’s scoring:

EnteroMedics (NASDAQ:RSLS) opened at $1.37 on Wednesday. EnteroMedics has a 1-year low of $1.23 and a 1-year high of $30.41.

EnteroMedics (NASDAQ:RSLS) last announced its quarterly earnings data on Tuesday, November 14th. The medical device company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.77). The firm had revenue of $0.36 million during the quarter. EnteroMedics had a negative net margin of 4,509.61% and a negative return on equity of 104.23%. equities analysts forecast that EnteroMedics will post -1.97 earnings per share for the current fiscal year.

A number of brokerages have recently commented on RSLS. Zacks Investment Research raised shares of EnteroMedics from a “hold” rating to a “strong-buy” rating and set a $2.25 target price on the stock in a report on Wednesday, August 23rd. ValuEngine raised shares of EnteroMedics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st.

ILLEGAL ACTIVITY WARNING: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at

EnteroMedics Company Profile

ReShape Lifesciences Inc, formerly EnteroMedics Inc, is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.

Receive News & Stock Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related stocks with our FREE daily email newsletter.